FDA Approves New Oral Pellet Formulation for Hereditary Angioedema Treatment

The FDA has approved BioCryst Pharmaceuticals' ORLADEYO (berotralstat) in a new oral pellet form. This once-daily prophylactic therapy is for adults and adolescents aged 12 and older with hereditary angioedema (HAE). The approval provides an alternative administration option for patients who struggle with swallowing capsules, potentially improving adherence and quality of life for those managing HAE.